Few people realise that the Emergency Use Authorisation (EUA)of the Pfizer-BioNTech Covid-19 Vaccine/BNT 162b2 was granted on the efficacy data of 170 patients. The 162 who received a placebo and 8 patients who were vaccinated formed the basis of the 95 per cent efficacy claims.
There has not been much discussion of these patients.
Already a subscriber? Log in
Subscribe for just $2 a week
Try a month of The Spectator Australia absolutely free and without commitment. Not only that but – if you choose to continue – you’ll pay just $2 a week for your first year.
- Unlimited access to spectator.com.au and app
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in